257.19
price up icon0.92%   2.34
after-market After Hours: 256.19 -1.00 -0.39%
loading
Alnylam Pharmaceuticals Inc stock is traded at $257.19, with a volume of 941.28K. It is up +0.92% in the last 24 hours and down -4.20% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$254.85
Open:
$256.14
24h Volume:
941.28K
Relative Volume:
1.08
Market Cap:
$30.64B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-118.52
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
+8.63%
1M Performance:
-4.20%
6M Performance:
-9.66%
1Y Performance:
+74.53%
1-Day Range:
Value
$253.83
$260.54
1-Week Range:
Value
$238.62
$260.54
52-Week Range:
Value
$143.81
$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,230
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-31-25 Initiated Redburn Atlantic Buy
Mar-24-25 Upgrade JP Morgan Neutral → Overweight
Nov-12-24 Downgrade Wolfe Research Peer Perform → Underperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-16-24 Upgrade Goldman Neutral → Buy
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

pulisher
06:27 AM

Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus

06:27 AM
pulisher
02:37 AM

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace

02:37 AM
pulisher
02:25 AM

Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com

02:25 AM
pulisher
Apr 28, 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe - simplywall.st

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha

Apr 28, 2025
pulisher
Apr 28, 2025

European Regulators Endorse Breakthrough ATTR-CM Treatment as Alnylam Hits All 10 Trial Endpoints - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Tr - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam (ALNY) Secures EMA Committee Support for Expanded Use of Vutrisiran | ALNY Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Alnylam’s vutrisiran gets positive CHMP opinion for ATTR-CM - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Alnylam (ALNY) Gains Positive CHMP Opinion for Amvuttra Label Ex - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Alnylam stock rises following CHMP’s positive opinion on Amvuttra By Investing.com - Investing.com Nigeria

Apr 25, 2025
pulisher
Apr 24, 2025

Homozygous Familial Hypercholesterolemia Market Poised - openPR.com

Apr 24, 2025
pulisher
Apr 24, 2025

Cns Specific Antisense Oligonucleotide Market Generated - openPR.com

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline - Yahoo Finance

Apr 24, 2025
pulisher
Apr 22, 2025

ATTR Amyloidosis Pipeline: 10+ Leading Companies Shaping the Future of Groundbreaking Therapies | DelveInsight - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Transthyretin Amyloidosis Treatment Market: Revenue Growth - openPR.com

Apr 22, 2025
pulisher
Apr 21, 2025

How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga

Apr 21, 2025
pulisher
Apr 21, 2025

BofA Raises Price Target on Alnylam (ALNY) Ahead of Q1 Earnings - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Rnai Technology Market to Witness Massive Growth by 2032 | - openPR.com

Apr 21, 2025
pulisher
Apr 21, 2025

Huntingtons Disease Treatment Market Projected To Witness - openPR.com

Apr 21, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results | ALNY Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Earnings Preview: RNAi Leader Alnylam Set to Unveil Q1 2025 Performance May 1What to Watch - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Coagulation Factor Deficiency Therapeutics Market Size in 7MM - openPR.com

Apr 16, 2025
pulisher
Apr 15, 2025

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

RNAi Therapeutics and Technology Market Key Players Analysis - openPR.com

Apr 15, 2025
pulisher
Apr 14, 2025

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? - Insider Monkey

Apr 14, 2025
pulisher
Apr 14, 2025

10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey

Apr 14, 2025
pulisher
Apr 14, 2025

High Growth Tech Stocks In US With Potential For Expansion - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

Morgan Stanley Lowers Alnylam (ALNY) Price Target Amid Earnings Preview | ALNY Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com

Apr 11, 2025
pulisher
Apr 10, 2025

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive - Endpoints News

Apr 09, 2025
pulisher
Apr 08, 2025

Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey

Apr 08, 2025

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
biotechnology ONC
$249.77
price up icon 0.12%
$104.00
price up icon 0.00%
$629.51
price up icon 1.38%
$23.62
price down icon 2.03%
$32.71
price up icon 0.52%
Cap:     |  Volume (24h):